QVQ has developed single domain antibodies in three major disease areas: Cancer, Infectious diseases and Age related disease like Neuromuscular diseases and osteoarthritis and osteoporosis,.
In the area of cancer imaging and therapy, QVQ has been involved in the CTMM Mammoth project, which aimed at developing new tools for optical imaging of breast tumors. This project delivered excellent VHHs against Her2 and CAIX, which are currently being produced under GMP conditions. QVQ also offers high affinity, well characterized VHHs directed against other cancer targets like EGFR, MET, uPAR, epCAM and Her3.
In the infectious disease area QVQ has a panel of VHH with a diversity of epitopes on HIV recognized by these VHH that can be used to investigate the various mechanisms of HIV-1 entrance and thereby help in the development of inhibition studies of the virus. High affinity well characterized VHH for p24, DC-SIGN and Hepatitis and many others are available.
In the Age related diseases osteoporosis and osteoarthritis, QVQ works together with Twente University to develop VHH that can improve the repair of bone tissue by combining a targeting moiety to the extracellular matrix combined with a capturing antibody that locally increases the level of endogenous growth factors which are beneficial for bone repair. Next to this, QVQ has VHH available against fibronectin, vitronectin, BMP6, 7,DKK and a broad range of molecules related to other diseases that can be repaired by Tissue Repair.
Many diseases like neuromuscular and osteoporosis are related to ageing although genetic components in these diseases are also important. In the neuromuscular area QVQ has been collaborating with LUMC in a FSHD foundation sponsored project to develop VHH that can improve the detection of FSHD muscular dystrophy. Next to this, QVQ has VHH available against vimentin, fibronectin, vitronectin, N-CAM and a broad range of molecules related to other muscular diseases. Moreover QVQ has VHH directed to neuro diseases like Alzheimer and Huntington
Check the list for your favorite molecule or contact firstname.lastname@example.org for more information on the possibilities of developing a high quality imaging agent for your molecule of interest
All products will be sold for research purposes only and will be custom made and functionalized for your application. Functionalization of these VHHs in order to generate high-end imaging agents include directional conjugation to IRDye800CW (LI-COR), Hylite dyes (Eurogentec), GFP, biotin, HRP, and NOTA.
A regular sample contains 250 μg of a (15kD) VHH. This equals ~17 nanomoles of antibody fragment, which equals ~2,5 mg conventional (150 kD) antibody to fulfill all research and imaging needs. Bulk quantities can be requested via email@example.com.
We are working hard to update our products and move them forward in development. The status of our current development can be found here.
Download the productlist in Excel (11-2017)
Phases of development
The development of VHH towards a high quality imaging agent involves 5 major steps. The products that are shown have an indication in which stage of development these products are. Below is described what the steps indicate:
Immunizations of llamas for this antigen have been performed, ready for monoclonal VHH selection.
Selection for monoclonal VHH have been performed, ready for further characterization.
Lead molecules with high affinity have been identified, ready for characterization in vitro.
VHH has been characterized in vitro and is readily available produced in E.coli and yeast.
VHH has been characterized in vivo, is produced in yeast and ready for production under GMP conditions.
VHH has been characterized in vitro and in vivo and is being produced under GMP conditions.
A stage or stages are in development. There can be one ore more stages in development at a time.